The short version of Lyophilised powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-23. Anything still debated is marked as such rather than presented as settled.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
=== Contraction === Neuromuscular junctions are the focal point where a motor neuron attaches to a muscle. Acetylcholine, (a neurotransmitter used in skeletal muscle contraction) is released from the axon terminal of the nerve cell when an action potential reaches the microscopic junction called a synapse. A group of chemical messengers across the synapse and stimulate the formation of electrical changes, which are produced in the muscle cell when the acetylcholine binds to receptors on its surface. Calcium is released from its storage area in the cell's sarcoplasmic reticulum. An impulse from a nerve cell causes calcium release and brings about a single, short muscle contraction called a muscle twitch. If there is a problem at the neuromuscular junction, a very prolonged contraction may occur, such as the muscle contractions that result from tetanus. Also, a loss of function at the junction can produce paralysis. Skeletal muscles are organized into hundreds of motor units, each of which involves a motor neuron, attached by a series of thin finger-like structures called axon terminals. These attach to and control discrete bundles of muscle fibers. A coordinated and fine-tuned response to a specific circumstance will involve controlling the precise number of motor units used. While individual muscle units' contract as a unit, the entire muscle can contract on a predetermined basis due to the structure of the motor unit. Motor unit coordination, balance, and control frequently come under the direction of the cerebellum of the brain.
Turquoise may also pseudomorphously replace feldspar, apatite, other minerals, or even fossils. Odontolite is fossil bone or ivory that has historically been thought to have been altered by turquoise or similar phosphate minerals such as the iron phosphate vivianite. Intergrowth with other secondary copper minerals such as chrysocolla is also common. Turquoise is distinguished from chrysocolla, the only common mineral with similar properties, by its greater hardness. Turquoise forms a complete solid solution series with chalcosiderite, CuFe6(PO4)4(OH)8·4H2O, in which ferric iron replaces aluminium.
In 1957, Marvin Margoshes and Bert L. Vallee at Harvard Medical School discovered that in horse kidney cortex, cadmium and zinc levels appeared to be maintained by binding to another molecule which they identified as a protein. They reported in the Journal of the American Chemical Society, concluding:The low sedimentation constant and high metal content of this material are indicative of a low molecular weight protein, probably containing a small number of cadmium atoms per molecule. Characterization of this unusual natural product is in progress.In 1958, Vallee presented the discovery at the International Congress of Biochemistry held in Vienna, and suggested that cadmium must be a natural biomolecule using the unknown protein. He pursued the research with his student Jeremias H. R. Kägi and was able to identify the new protein in 1960. The conclusion in The Journal of Biological Chemistry runs:The present study reports the isolation and characterization of a protein from equine renal cortex which contains 2.9% of cadmium, 0.6% of zinc, and 4.1% of sulfur per g dry weight of protein. This protein has been termed metallothionein in view of its metal and sulfur content.Vallee and Kägi reported further confirmation in the same journal in 1961. They later realised that metallothionein was not a single type of protein. With their collaborators, they could differentiate another related protein but with different amino acid properties and gave the name "metallothionein-1B" in 1970.
=== Type I === A civilization "close to the level currently achieved on Earth, with an energy consumption of ≈4×1019 erg/s" (≈4×1012 watts). A Type I civilization is usually defined as one that can harness all the energy that reaches its home planet from its parent star (for Earth, this value is about 2×1017 watts), which is about four orders of magnitude higher than the amount currently achieved on Earth, with an energy consumption of ≈2×1013 watts by 2020. The astronomer Guillermo A. Lemarchand defined Type I as a level close to today's terrestrial civilization, with an energy capacity equivalent to Earth's solar irradiance, between 1016 and 1017 watts.
Sources: en.wikipedia.org
=== Available forms === PSGAG is first administered as a series of injections over several weeks, and can be continued once or twice a month thereafter. It is normally injected intramuscularly, though can also be injected intra-articularily (directly into the joint) in horses or subcutaneously in off-label uses. Giving PSGAG intra-articularily requires it to be given aseptically, and is sometimes supplemented by the antibiotic amikacin to prevent infection. There are no generic or human-labeled equivalents of PSGAG in the US.
On 17 February, an Israeli drone strike hit a car in Sidon, killing Mohammed Shaheen, Hamas's operations chief in Lebanon. On the ceasefire's deadline on 18 February, the IDF withdrew from all of southern Lebanon, apart from five hilltops on the border—namely al-Aziyah, al-Awaida, el-Hamames, Jabal Bilat, and Labbouneh. On 22 March, six rockets were fired at Metula from southern Lebanon, with three crashing in Lebanon and the rest being intercepted. Hezbollah denied responsibility for the attack. The IDF responded with strikes on dozens of Hezbollah targets across southern Lebanon, including rocket launchers. On 25 March, an Israeli drone strike on a vehicle in Qaaqaait al-Jisr killed Hassan Kamal Halawi, who commanded Hezbollah's anti-tank missile unit in southern Lebanon. On 28 March, two rockets were fired at Kiryat Shmona, with one falling short in Lebanon and the other being intercepted. In response, the IDF said that it struck several Hezbollah targets in southern Lebanon, including command centers. A strike in Kfar Tebnit killed three people and injured 18 others. An airstrike also hit a building in Dahieh that the IDF accused of storing drones from Hezbollah's Unit 127, in the first attack in Beirut since the ceasefire went into effect. On 1 April, an Israeli airstrike on an apartment in Dahieh killed four people and injured seven others. Among the dead were senior Hezbollah official Hassan Bdeir, who the IDF accused of planning to attack Israeli civilians alongside Hamas, and his son, who was a Hezbollah member.
==== Above-ground disposal ==== Dry cask storage typically involves taking waste from a spent fuel pool and sealing it (along with an inert gas) in a steel cylinder, which is placed in a concrete cylinder which acts as a radiation shield. It is a relatively inexpensive method which can be done at a central facility or adjacent to the source reactor. The waste can be easily retrieved for reprocessing.
Sources: en.wikipedia.org
Takamine Tokumei from Shuri, Ryūkyū Kingdom, is reported to have made a general anesthesia in 1689 in the Ryukyus, now known as Okinawa. He passed on his knowledge to the Satsuma doctors in 1690 and to Ryūkyūan doctors in 1714. Hanaoka Seishū (華岡 青洲, 1760–1835) of Osaka was a Japanese surgeon of the Edo period with a knowledge of Chinese herbal medicine, as well as Western surgical techniques he had learned through Rangaku (literally "Dutch learning", and by extension "Western learning"). Beginning in about 1785, Hanaoka embarked on a quest to re-create a compound that would have pharmacologic properties similar to Hua Tuo's mafeisan. After years of research and experimentation, he finally developed a formula which he named tsūsensan (also known as mafutsu-san). Like that of Hua Tuo, this compound was composed of extracts of several different plants, including:
==== Later years ==== Adorno began writing an introduction to a collection of poetry by Rudolf Borchardt, which was connected with a talk entitled "Charmed Language," delivered in Zürich, followed by a talk on aesthetics in Paris, where he met Beckett again. Beginning in October 1966, Adorno took up work on Aesthetic Theory. In June 1969, he completed Catchwords: Critical Models. During the winter semester of 1968–1969 Adorno was on sabbatical leave from the university and thus able to dedicate himself to the completion of his book of aesthetics. For the summer semester, Adorno planned a lecture course entitled "An Introduction to Dialectical Thinking," as well as a seminar on the dialectics of subject and object. But at the first lecture, Adorno's attempt to open up the lecture and invite questions whenever they arose degenerated into a disruption from which he quickly fled. After a student wrote on the blackboard, "If Adorno is left in peace, capitalism will never cease," three women students approached the lectern, bared their breasts and scattered flower petals over his head. Yet, Adorno continued to resist blanket condemnations of the protest movement, which would have only strengthened the conservative thesis according to which political irrationalism was the result of Adorno's teaching. After further disruptions to his lectures, Adorno cancelled the lectures for the rest of the seminar, continuing only with his philosophy seminar.
Some mushrooms are used in folk medicine. In a few countries, extracts, such as polysaccharide-K, schizophyllan, polysaccharide peptide, or lentinan, are government-registered adjuvant cancer therapies, but clinical evidence for efficacy and safety of these extracts in humans has not been confirmed. Although some mushroom species or their extracts may be consumed for therapeutic effects, some regulatory agencies, such as the US Food and Drug Administration, regard such use as a dietary supplement, which does not have government approval or common clinical use as a prescription drug.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.